Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system
Our study offers a deeper and broader understanding of the pulmonary safety profile of amiodarone, which will aid healthcare professionals in mitigating the risk of pulmonary adverse events in clinical practice.
Authors
- Di Ge (ORCID: https://orcid.org/0000-0001-5241-1766)
- Wenge Su
- Mengfan You
- Yifei Wang (ORCID: https://orcid.org/0000-0002-4602-349X)
- Yunxiao Shang (ORCID: https://orcid.org/0000-0003-4110-1177)
- Guangheng Zhang (ORCID: https://orcid.org/0009-0008-3984-4610)
- Jingrong Yang (ORCID: https://orcid.org/0000-0003-1061-560X)
- Kaidi Xing
- Han Zhang (ORCID: https://orcid.org/0009-0000-8542-2509)
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1080/14740338.2024.2438742
- Citations
- 4
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 1.61